Altimmune (ALT) Tax Provisions (2012 - 2025)

Altimmune's (ALT) quarterly Tax Provisions came in at -$18.0 million in Q4 2025, down 2538.03% on a QoQ basis from -$681000.0 in Q1 2025.

Altimmune (ALT) Tax Provisions (2012 - 2025) Analysis & Trends

Altimmune (ALT) has 11 years of Tax Provisions data on file, last reported at -$18.0 million in Q4 2025.

On a quarterly basis, Tax Provisions changed N/A year-over-year to -$18.0 million in Q4 2025; TTM through Dec 2025 was -$18.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$18.6 million, up 6.59% from the prior year.
Tax Provisions for Q4 2025 stood at -$18.0 million, down from -$681000.0 in the prior quarter.
Over the last five years, Tax Provisions for ALT reached as high as $144000.0 in Q4 2022 and fell as low as -$18.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	125,146.46
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	31.86 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-60.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Altimmune	346.63 Mn	346.63 Mn	-	-

Download Data